Abstract:Thank you for submitting your manuscript on Smad3 monoubiquitination by Smurf2 for consideration by The EMBO Journal. We have now received the comments of three expert reviewers, copied below. While the referees consider your findings potentially interesting and the study overall well-done, they however raise serious concerns regarding the conclusiveness of the data and the experimental support for the main conclusions. The extent of this criticisms, I am afraid to say, appears to preclude publication in The EMBO Journal, at least in the present form. Nevertheless, given the interest in principle, I am willing to give you an opportunity to respond to the referees' criticisms through a revised version. It is however clear that for the manuscript to eventually become suitable for publication in these pages, a significant amount of revision effort will be required, and I also realize that not all of the requested manuscript may be technically feasible I would therefore also understand if you were to decide to rather publish the manuscript rapidly and without major changes elsewhere. Should you however decide to thoroughly revise the study for The EMBO Journal, I would in fact not insist on clarification of the underlying genetic redundancies among Smad-regulating ubiquitin ligases, nor on the absence of mouse phenotypes. What would however be absolutely required is a thorough mechanistic clarification on the cellular level, in particular to show that Smad3 is regulated by Smurf2 on the endogenous level in the absence of exogenous overexpression. It will also be essential to address the question of monovs. multi-monovs. poly-ubiquitination raised by all referees, and to clarify the impact of Smurf2 on Smad2 relative to Smad3. Finally, the referees are unconvinced by the present evidence for Smad3 monoubiquitination affecting signaling via complex disruption, and more compelling data will be needed to address this.

The Post-translational Modifications of Smurf2 in TGF-beta Signaling

Posttranslational Regulation of Smads

Smurf2 is a Ubiquitin E3 Ligase Mediating Proteasome-dependent Degradation of Smad2 in Transforming Growth Factor-β Signaling

Smurf1 polyubiquitinates on K285/K282 of the kinases Mst1/2 to attenuate their tumor-suppressor functions.

Post-translational regulation of TGF-β receptor and Smad signaling.

Post‐translational Regulation of TGF‐β Receptor and Smad Signaling

Smurf1 Polyubiquitinates on K285/K282 of the Kinases Mst1/2 to Attenuate Their Tumor-Suppressor Functions

Ablation of Smurf2 reveals an inhibition in TGF-β signalling through multiple mono-ubiquitination of Smad3.

Regulation of TGF-β Superfamily Signaling by SMAD Mono-Ubiquitination

Regulation of TGF-beta signalling by protein phosphatases.

Regulation of Smad Functions Through Ubiquitination and Sumoylation Pathways

The Regulation of TGF-β/SMAD Signaling by Protein Deubiquitination

Key Role for Ubiquitin Protein Modification in TGFβ Signal Transduction

Reversible Ubiquitination Regulates the Smad/TGF-β Signalling Pathway

Ablation of Smurf 2 reveals an inhibition in TGF-β signaling through mono-ubiquitination of Smad 3

Ubiquitin Ligase Smurf1 Targets TRAF Family Proteins for Ubiquitination and Degradation

Downregulation of Smurf2 ubiquitin ligase in pancreatic cancer cells reversed TGF-β-induced tumor formation

SUMOylation of Smad2 mediates TGF-β-regulated endothelial-mesenchymal transition

To (TGF)β or not to (TGF)β: Fine-tuning of Smad signaling via post-translational modifications

To (TGF)beta or not to (TGF)beta: fine-tuning of Smad signaling via post-translational modifications.

Posttranslational Modifications of TGF-β Receptors.